Clinical Scorecard: Evaluating EGFR Gene Mutations in Lung Adenocarcinoma: The Role of a Combined Model Utilizing 18F-FDG PET/CT Radiomics and Tumor Habitat Analysis
At a Glance
Category
Detail
Condition
Lung Adenocarcinoma
Key Mechanisms
EGFR mutation status prediction using 18F-FDG PET/CT radiomics and tumor habitat analysis.
Target Population
Patients with lung adenocarcinoma.
Care Setting
Clinical settings utilizing imaging and radiomics.
Key Highlights
Combined model achieved AUC = 0.862 for EGFR mutation prediction.
Habitat model showed AUC = 0.831, both outperforming other models.
SHAP analysis identified key predictive features primarily from CT data.
Guideline-Based Recommendations
Diagnosis
Utilize baseline 18F-FDG PET/CT radiomics for predicting EGFR mutation status.
Management
Implement image-informed personalized treatment based on predictive model outcomes.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
724 patients from two centers.
Models developed to enhance prediction of EGFR mutation status.
Clinical Best Practices
Incorporate tumor habitat analysis with radiomics for improved predictive accuracy.
